Добірка наукової літератури з теми "Complication thrombotique"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Complication thrombotique".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "Complication thrombotique":
MÉRIC, M., M. HOUBERDON, and P. LAFOURCADE. "Thrombose veineuse d’effort du membre inférieur: une pathologie du sport à ne pas méconnaître." Revue Médecine et Armées, Volume 43, Numéro 5 (December 1, 2015): 479–83. http://dx.doi.org/10.17184/eac.6930.
Gorgi, K., F. Toulali, F. Kamel, K. Rifai, H. Iraqi, and M. E. H. Gharbi. "Complication thrombotique chez le diabétique en cétoacidose : à propos d’un cas." Annales d'Endocrinologie 82, no. 5 (October 2021): 487. http://dx.doi.org/10.1016/j.ando.2021.08.681.
Guanella, Raphaël. "Syndrome post-thrombotique : la complication négligée de la maladie thromboembolique veineuse." Revue Médicale Suisse 9, no. 372 (2013): 321–25. http://dx.doi.org/10.53738/revmed.2013.9.372.0321.
Farah, R., M. Lambert, A. L. Fauchais, V. Queyrel, U. Michon-Pasturel, M. Hebbar, E. Hachulla, P. Y. Hatron, and B. Devulder. "Syndrome de Gougerot-Sjögren et purpura thrombotique thrombocytopénique, une complication exceptionnelle : à propos d'un cas." La Revue de Médecine Interne 22 (December 2001): 538s. http://dx.doi.org/10.1016/s0248-8663(01)80244-7.
Merdji, Hamid, Laurent Sattler, Sibylle Cunat, Ferhat Meziani, and Julie Helms. "Hémostase et COVID-19." Médecine Intensive Réanimation 30, Hors-série 1 (June 16, 2021): 35–42. http://dx.doi.org/10.37051/mir-00062.
Masmoudi, W., E. Ezine, L. Adelmand, S. Chantepie, and L. Verneuil. "La microangiopathie thrombotique (MAT) : une complication à rechercher dans les lymphomes T épidermotropes traités par gemcitabine." Annales de Dermatologie et de Vénéréologie 144, no. 12 (December 2017): S277. http://dx.doi.org/10.1016/j.annder.2017.09.456.
Mutchmore, Alexandre, Dominique Toupin, Geneviève Le Templier, and Bobby Gouin. "Bilateral Asynchronous Adrenal Infarction in JAK2-Positive Essential Thrombocythemia." Canadian Journal of General Internal Medicine 18, no. 1 (March 25, 2023): 66–70. http://dx.doi.org/10.22374/cjgim.v18i1.667.
Tejpal, Ambika, Peter Economopoulos, Roseann Andreou, and James Stevenson. "Vaccine-Induced Immune Thrombotic Thrombocytopenia after Receiving the ChAdOx1 nCoV-19 Vaccine." Canadian Journal of General Internal Medicine 16, no. 2 (June 21, 2021): 34–37. http://dx.doi.org/10.22374/cjgim.v16i2.559.
Nou-Howaldt, M., V. Monnin-Bares, J. P. Laroche, C. Calais, A. Blouet, P. Lhorte, and I. Quéré. "Une complication inhabituelle postangioplastie veineuse dans le cadre de la prise en charge d’un syndrome post-thrombotique : l’endothélialisation intrastent, à propos d’un cas clinique." JMV-Journal de Médecine Vasculaire 43, no. 2 (March 2018): 126–27. http://dx.doi.org/10.1016/j.jdmv.2017.12.116.
Darnige, L., and A. Lillo-Le Louët. "Traitements par immunoglobulines et complications thrombotiques." La Revue de Médecine Interne 35, no. 1 (January 2014): 39–44. http://dx.doi.org/10.1016/j.revmed.2013.07.006.
Дисертації з теми "Complication thrombotique":
Gourvil, Lemoigne Emmanuelle. "Place de l'infection à VIH dans la microangiopathie thrombotique : à propos d'un cas de microangiopathie thrombotique révélateur d'une infection à VIH." Bordeaux 2, 1993. http://www.theses.fr/1993BOR23103.
Mallol, Carola. "Syndrome des anticorps antiphospholipides : place des anticorps antiphosphatidylsérine dans les complications thrombotiques." Montpellier 1, 2000. http://www.theses.fr/2000MON11140.
Gautier, Éric. "Les micro-angiopathies thrombotiques chez la femme enceinte." Bordeaux 2, 1990. http://www.theses.fr/1990BOR25159.
Javorschi, Sandrine. "Evolution de l'hémostase avec l'âge : effet de la pathologie thrombotique et résistance à la protéine C activée." Bordeaux 2, 1996. http://www.theses.fr/1996BOR2P053.
Chauleur, Céline. "Identification des facteurs de risque pour prévenir les complications thrombotiques et hémorragiques de la grossesse." Saint-Etienne, 2009. http://www.theses.fr/2009STET003T.
Kalawon, Ramesh. "Traitement de la maladie post-thrombotique fémorale par transposition saphéno-poplitée : à propos de 9 cas." Bordeaux 2, 1995. http://www.theses.fr/1995BOR2M169.
Moussa, Mouhamed Djahoum. "Déterminants cliniques, physiopathologiques et pronostics associés aux complications liées à l’hémostase au cours des assistances circulatoires de courte durée à pompe centrifuge." Electronic Thesis or Diss., Université de Lille (2022-....), 2022. http://www.theses.fr/2022ULILS055.
The purpose of this dissertation is to characterize hemostasis-related complications in patients supported by peripheral VA-ECMO to improve their prevention and to optimize the antithrombotic therapeutic approaches in use. In a first study, we qualitatively and quantitatively described the composition of thrombi collected from the VA-ECMO circuits. We observed that these thrombi are mainly made of VWF, fibrin and in a lesser proportion of platelets and RBCs. Our quantitative approach also allowed us to demonstrate the presence of NETs while there was no active septic, confirming the possibility of aseptic NETosis under VA-ECMO. By hierarchical cluster analysis, we identified 2 types of thrombi, each of which may be related to a different mechanism of formation. In this study, the location of thrombi on the VA-ECMO circuit did not impact their compositions, highlighting the heterogeneity of thrombi formed within VA-ECMO and the multifactorial mechanisms that support thrombosis in this setting. In a second study, we compared the performance of surface coatings on VA-ECMO circuits to reduce thrombinoformation and its clinical consequences. Two of the most used coatings in daily practice were compared: the phosphorylcholin-based coating and the polysaccharide-albumin-based coating. We observed a higher rate of thrombotic complications in the phosphorylcholin group without any excess bleeding events or mortality in either group. In addition, compared with thrombi from phosphorylcholin-coated circuit junctions, those from polysaccharide-albumin-coated circuits were poorer in VWF. Our work suggests that the level of anticoagulation should be modulated according to the type of coating of the ECMO circuit.The aim of our third study was to identify the most relevant bleeding events that may guide clinical decision-making for more aggressive clinical management and a greater investment in research. To this end, we compared the association between 3 bleeding classifications with 28-day mortality. The ELSO definition already in use and the BARC classification classes ≥ type 2 were associated with 28-day mortality and thus retained as definitions of major bleeding. Laboratory parameters that are predictors major bleeding according to the ELSO definition were decreased fibrinogen, platelet count, and hemoglobin at cannulations. Body mass index and postcardiotomy etiology were also predictive of ELSO major bleeding. In an additional work related to the topic of the thesis, we studied two of the most used laboratory tests for the monitoring of systemic heparin during VA-ECMO, the APTT and the Anti-Xa activity, to identify the most relevant. First, we studied the relationship between these two tests and then analyzed in a second objective the impact of biological influencing factors on this relationship. Next, we determined their associations with thrombotic and hemorrhagic complications. Although linearly associated, the rate of discordance between their measurements was 39 % for an Anti-Xa reference range of 0.3 - 0.7 IU/mL. Neither APTT nor Anti-Xa was associated with thrombotic or bleeding complications. Taken together, our results highlight the heterogeneity of thrombi from peripheral VA-ECMO, the involvement of numerous causal factors that underline thrombotic and hemorrhagic complications, both not predictable by routine tests. Finally, our work underscored the need for new approaches in thrombotic or hemorrhagic complications management with targets set at an individual level considering both patient and ECMO circuit characteristics
Moustey, Francois. "Le syndrome catastrophique des antiphospholipides : état actuel des connaissances. Expérience personnelle : à propos d'un cas." Bordeaux 2, 2001. http://www.theses.fr/2001BOR2M042.
Poline, Diane. "Apport de l'échocardiographie transœsophagienne dans le choix du traitement des thromboses de prothèse valvulaire cardiaque : à propos de 69 épisodes thrombotiques." Bordeaux 2, 1994. http://www.theses.fr/1994BOR23017.
Dandachli, Mourad. "L’efficacité du CD154 monomérique dans le traitement des complications thrombotiques." Thèse, 2016. http://hdl.handle.net/1866/19251.
CD154 has emerged as an important player in the pathogenesis of several autoimmune diseases, as well as vascular dysfunctions. CD154 is a member of the tumour necrosis factor family of pivotal importance in humoral immunity. However, CD154 also shares critical inflammatory functions through its interaction with its classical CD40 receptor or recently identified binding partners, namely αIIbβ3, α5β1 and αMβ2. These responses imply CD154 as a key factor in chronic inflammatory disorders including autoimmune diseases and thrombosis. Disrupting the interaction of CD154 with its receptors through anti-CD154 Abs significantly inhibits the development of these diseases, albeit serious side effects have been associated with these therapies. To overcome these adverse effects, other approaches such as knockout, antisense oligonucleotide and siRNA targeting were developed. These approaches were focused on the CD154/CD40 interaction and did not address the interaction of CD154 with its other receptors. Thus, there is a need for novel CD154 treatments for the prevention/abrogation of inflammatory or autoimmune diseases that address all CD154 receptors. Our group profoundly investigated the structural/functional interaction of CD154 with its various receptors. Given the importance of the trimeric structure of CD154 for its biological activity, we generated monomeric form of the molecule that can specifically bind to one receptor without inducing intracellular activation. This agent represents a potential therapeutic tool for the treatment of CD154-mediated diseases such as thrombotic events.